UNSPSC 51123003: Sparteine

This classification denotes an antiarrhythmic and oxytocic quinolizidine alkaloid with the molecular formula C15H26N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 298897D62S, chemically known as 6-beta,7-alpha,9-alpha,11-alpha-pachycarpinE but more generally known as sparteine, which bears US NIH Compound Identifier 644020. The term SPARTEINE is an International Non-Proprietary Name or INN.

European Medicines Agency schedules sparteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10613MIG. Most nations, for tariff and trade purposes, schedule sparteine under HS 29399900 and SITC 54149. As of Q4 2014, SPARTEINE remains US FDA's Preferred Term for this commodity. SMILES: C1CCN2CC3CC(C2C1)CN4C3CCCC4.

UNSPSC 51123003 Sparteine (Commodity) covers emergency medical and pharmaceutical supply procurement by state and local health agencies, fire departments, and multi-state cooperative purchasing alliances — specifically the acquisition of injectable medications and pharmaceutical products for emergency medical services, hospital use, and state health program distribution. The code reflects actual purchasing of advanced life support medications (epinephrine, labetalol, adenosine, diltiazem), generic multi-source pharmaceuticals, and over-the-counter products through state and local procurement channels rather than federal medical supply acquisition. Buying entities include municipal fire rescue departments, state health commissions, and multi-state cooperative purchasing alliances that aggregate demand across participating government jurisdictions. Vendors must meet FDA compliance, current Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and supply chain security requirements including expiration-date warranties and product replacement obligations.

Recent solicitations span three jurisdictional tiers: the City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026 for Advanced Life Support Medications (response due April 8, 2026, estimated contract value $40,000) to supply Tampa Fire Rescue with four specific medication line items; the Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to assess vendor capability for direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 on January 20, 2026 (response due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson across Minnesota, Oregon, and other participating jurisdictions. Activity concentrates in Florida, Texas, and the Upper Midwest, with MMCAP's multi-state cooperative model representing a significant vehicle for aggregated pharmaceutical procurement across state and local government facilities.